Talphera (TLPH) Change in Receivables (2015 - 2025)

Talphera (TLPH) posted quarterly Change in Receivables of $27000.0 for Q1 2025, down 70.65% quarter-over-quarter from $92000.0 in Q4 2023.

Talphera (TLPH) Change in Receivables (2015 - 2025) Analysis & Trends

Talphera's Change in Receivables history runs 10 years deep, the most recent figure standing at $27000.0 for Q1 2025.

In Q1 2025, Change in Receivables changed N/A year-over-year to $27000.0; the TTM figure through Mar 2026 stood at $119000.0 (up 56.58% YoY), while the FY2023 annual figure was $189000.0, up 26.85% from the prior year.
Change in Receivables for Q1 2025 stood at $27000.0, down from $92000.0 in the prior quarter.
The five-year high for Change in Receivables was $180000.0 in Q2 2022, with the low at -$554000.0 in Q2 2021.
The 4-year median for Change in Receivables is $24000.0 (2022), against an average of -$8461.5.
Peak annual rise in Change in Receivables reached 202.04% in 2022, while the deepest fall reached 3000.0% in 2022.
Talphera's Change in Receivables stood at $7000.0 in 2021, then sank by 3000.0% to -$203000.0 in 2022, then soared by 145.32% to $92000.0 in 2023, then sank by 70.65% to $27000.0 in 2025.
Business Quant data shows TLPH's Change in Receivables at $27000.0 in Q1 2025, $92000.0 in Q4 2023, and -$43000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	91.00 Mn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	66.00 Mn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	-445.26 Mn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-1.70 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	126.50 Mn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	84.30 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Talphera	90.63 Mn	90.63 Mn	-	-

Download Data